Palantir to report; Trump on Nvidia chip exports - what’s moving markets
CapsoVision, Inc. (NASDAQ:CV) reported a planned leadership transition in its clinical operations team, according to a statement released in a recent SEC filing.
On Monday, Rebecca Petersen notified CapsoVision of her upcoming retirement as Senior Director of Clinical Affairs, effective October 15. The company has promoted Keri Jorgenson to Director of Clinical Operations. Ms. Jorgenson, along with the existing clinical operations team, will assume responsibility for the company’s clinical development operations and activities.
Ms. Jorgenson joined CapsoVision in March 2022 and most recently served as Senior Clinical Project Manager. The company stated that she has worked closely with Ms. Petersen and the broader clinical operations team during her tenure.
To support the transition, Ms. Petersen has agreed to provide consulting services to CapsoVision and the clinical operations team. She will enter into a consulting agreement effective October 16, under which she will be paid $150 per hour. The agreement may be terminated by either party with three days’ notice. During her consulting period, Ms. Petersen’s outstanding unvested employee stock options will continue to vest according to their existing schedule.
CapsoVision indicated in the filing that it does not anticipate any disruption to its clinical development operations during this transition. The company also stated that the full text of Ms. Petersen’s consulting agreement will be filed with its Quarterly Report on Form 10-Q for the three months ending September 30, 2025.
This information is based on a press release statement included in CapsoVision’s recent SEC filing.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.